AstraZeneca Plans Direct NYSE Listing, Retains U.K. Presence as Shares Gain

AstraZeneca, the UK’s largest pharmaceutical company, has announced plans to directly list its shares on the New York Stock Exchange (NYSE), transitioning from its current Nasdaq-traded American Depositary Receipts (ADRs). This strategic move aims to broaden global investor access, particularly enabling U.S. pension fund investments, while reaffirming that its headquarters will remain in Cambridge, England, and it will stay listed on the London Stock Exchange.